Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00206752 · ClinicalTrials.gov registry record · NA

Study of Unilateral Neck Irradiation in Patients With SCC of the Head and Neck

A NA study of Squamous Cell Carcinoma of the Head and Neck, sponsored by Beth Israel Medical Center.

Completed
Registry status
NA
Development phase
45
Enrollment target
1
Study location

NCT00206752: Completed NA study of Squamous Cell Carcinoma of the Head and Neck, sponsored by Beth Israel Medical Center.

NCT00206752 is a NA study of Squamous Cell Carcinoma of the Head and Neck that has completed, run by Beth Israel Medical Center. The registered enrollment target is 45 participants, below the 145-participant average among 29 other Squamous Cell Carcinoma of the Head and Neck trials with a reported enrollment target (69% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00206752, a NA study of Squamous Cell Carcinoma of the Head and Neck, has completed, sponsored by Beth Israel Medical Center.

COMPLETED
Registry status
NA
Development phase
45 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to assess the feasibility of avoiding opposite side neck radiation therapy in patients with clearly one side squamous cell cancer of the head and neck. We aim to assess the reduction in treatment volume (amount of radiation therapy required), and the resultant xerostomia and mucositis, with the delivery of unilateral neck radiation therapy.

Interventions

  • RADIATION Radiation therapy
  • RADIATION definitive external beam radiation in the ipsilateral neck

Study Locations (1)

New York

  • Beth Israel Medical Center - New York

Trial Details

FieldValue
Enrollment Target 45 participants
Start Date 2004-08
Est. Completion 2015-02
Phase NA
Beth Israel Medical Center

44 total trials

What the finished NCT00206752 record still lists

NCT00206752 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 145-participant average among 29 other Squamous Cell Carcinoma of the Head and Neck trials with a reported enrollment target (69% lower).

The record links to 1 condition, with Squamous Cell Carcinoma of the Head and Neck appearing as the primary indexed condition, and to 2 interventions - of which Radiation therapy is the first listed.

NCT00206752 reports a single indexed study location in New York.

Frequently Asked Questions

What is clinical trial NCT00206752 about?

NCT00206752 is a clinical study titled "Study of Unilateral Neck Irradiation in Patients With SCC of the Head and Neck". The purpose of this study is to assess the feasibility of avoiding opposite side neck radiation therapy in patients with clearly one side squamous cell cancer of the head and neck. We aim to assess the reduction in treatment volume (amount of radiation therapy required), and the resultant xerostomia...

What is the current status of trial NCT00206752?

This trial is currently completed. It is a NA study. The enrollment target is 45 participants. The study started on 2004-08. Estimated completion is 2015-02.

What conditions does trial NCT00206752 study?

This clinical trial studies the following conditions: Squamous Cell Carcinoma of the Head and Neck.

What interventions are being tested in trial NCT00206752?

The interventions under investigation include: Radiation therapy (RADIATION), definitive external beam radiation in the ipsilateral neck (RADIATION).

Who is sponsoring clinical trial NCT00206752?

This trial is sponsored by Beth Israel Medical Center, which has 44 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00206752 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Squamous Cell Carcinoma of the Head and Neck

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00206752's enrollment target sits among peer trials

45 18th of 29 higher than 12 of 29 other Squamous Cell Carcinoma of the Head and Neck trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Squamous Cell Carcinoma of the Head and Neck trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00804154 · 45 participants · Phase 1

    Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer

  • NCT01851694 · 45 participants · NA

    Beta-cell Response to Incretin Hormones in Cystic Fibrosis

  • NCT02896335 · 45 participants · Phase 2

    Palbociclib and Pembrolizumab In Central Nervous System Metastases

  • NCT03454035 · 45 participants · Phase 1

    Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00206752, the US trial registry maintained by the National Library of Medicine. NCT00206752 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.